
Radiation oncologist @MayoRadOnc @MayoClinic | views = my own
Rochester, MN
Joined March 2020
- Tweets151
- Following393
- Followers596
- Likes471
Alexander Sherry retweeted
Excited for the interest in our biomarker work from the urologic oncology community @VincentWenxinXu @PavlosMsaouel @AlexSherryMD @kieko_hara @d_shapiro1 @MDAndersonnews
🏆 Congratulations to @ChadTangMD et al. on receiving our April IMPACT Award!
This month's winning paper stands out for its contribution to understanding how we can better predict outcomes for patients with Oligometastatic Clear-cell Renal Cell Carcinoma — an important step forward for personalised care.
Well deserved. 👏
#IMPACTAward #EuropeanUrology #renalcellcarcinoma #Oncology #Urology
Alexander Sherry retweeted
Replying to @GiulioFrancoli1
@GiulioFrancoli1 at #estro2026 presents early results of the randomized PERSIAN trial. Results are early showing excellent PSA response in both arms (mdt slightly better) but definitely more to come.
6/ EXTEND supports MDT+SOC as a strategy in oligometastasis and opens the door to multiple promising new directions to further improve outcomes with MDT in oligometastasis,. such as ctDNA guided care meriting future RCTs
7/ My personal gratitude to PI @ChadTangMD for years of mentorship and guidance on this study. Full paper available here: ascopubs.org/doi/pdf/10.1200…
Alexander Sherry retweeted
New @EurUrol! Pooled trials @PeterMacCC / @UTMDAnderson shows adding Pembrolizumab to MDT for oligometastatic #kidneycancer ⬆️ PFS (28 vs 17 mo; HR 0.57), esp. after prior therapy - shorturl.at/WWvBg - Correlative data confirm MDT+ICI-evoked immune activation #Kcsm #RadOnc
Alexander Sherry retweeted
Excited to review our paper on KIM-1 and ctDNA in oligomet RCC and the K-COMPASS prognostic model published this wk in @EuropeanUrology. Great collaboration between @UTMDAnderson and @DanaFarber. Specifically @VincentWenxinXu and @DrChoueiri
Full paper: authors.elsevier.com/a/1mhMr…
Alexander Sherry retweeted
This is how we finally start harnessing the untapped for decades power of *prognostic* modeling (not “predictive”) for biomarker development. Onwards! 🔬@ChadTangMD @VincentWenxinXu @AlexSherryMD @OncHahn @AmandaNizamMD @KidneyCancer @ebludmir @PGrivasMDPhD
The K-COMPASS study by @ChadTangMD shows how ctDNA and KIM-1 are prognostic and can be used to estimate treatment-free survival in patients with oligometastatic RCC #ASCOGU26 @PavlosMsaouel
Alexander Sherry retweeted
At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.
Alexander Sherry retweeted
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6….
The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.
Alexander Sherry retweeted
Thanks for @Uromigos for letting me chat about radiation in oligometastatic RCC. @_ShankarSiva @piet_ost @ndesai2005 @KidneyCancer @AlexSherryMD @ebludmir @ASTRO_org @ACKoongMDPhD @MDAndersonNews @VedangMurthy @PavlosMsaouel @salvolarosa
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Chad Tang discusses: Metastasis-directed Therapy in RCC.
Alexander Sherry retweeted
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics
authors.elsevier.com/a/1ljMf…
Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca?
Happy to share the results of EXTEND evaluating this question alongside PI @ChadTangMD & many others
10/
Nonetheless EXTEND is a critical step forward for improving outcomes in oligomet prostate ca and supports the role of MDT with multiple ADT strategies.
11/
Many thanks to the outstanding study team/coordinators, collaborators & the pts and families who participated in the trial. My special gratitude for the mentorship of @ChadTangMD in this study.
Full text:
authors.elsevier.com/c/1lX0v…





























